Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas

  • Authors:
    • S. Yutani
    • S. Shichijo
    • Y. Inoue
    • N. Kawagoe
    • K. Okuda
    • T. Kurohiji
    • M. Tanaka
    • M. Sata
    • K. Itoh
  • View Affiliations

  • Published online on: March 1, 2001     https://doi.org/10.3892/or.8.2.369
  • Pages: 369-372
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We previously reported a tumor-rejection antigen, SART1259, possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTL) in epithelial cancer patients. The present study investigated the expression of the SART1259 antigen in hepatocellular carcinomas (HCC) in order to explore for a potential molecule for use in specific immunotherapy of HCC patients. Expression of the SART1 antigens in samples was analyzed by western blot analysis with anti-SART1259 and anti-SART1800 polyclonal antibodies. In addition HLA-A24- restricted CTLs were induced from peripheral blood mononuclear cells (PBMCs) of HLA-A24+ HCC patients by the SART1690-698 (EYRGFTQDF) peptide with an HLA-A24 binding motif. The SART1259 antigen was detected in the cytoplasmic fraction of 6 of 8 HCC cell lines and 12 of 23 (52%) HCC tissues, but in none of the normal liver tissues or those of chronic hepatitis or cirrhosis. The HLA-A24 restricted and SART1-specific CTLs recognized the HLA-A24+ and SART1259+ HCC cells. Further, in peripheral blood mononuclear cells of HCC patients, the SART1690-698 peptide induced CTLs that reacted to the HCC cells in an HLA-A24-restricted manner. These results suggest that the SART1259 antigen could be an appropriate target molecule for use in specific immunotherapy of HCC patients.

Related Articles

Journal Cover

March-April 2001
Volume 8 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yutani S, Shichijo S, Inoue Y, Kawagoe N, Okuda K, Kurohiji T, Tanaka M, Sata M and Itoh K: Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas. Oncol Rep 8: 369-372, 2001.
APA
Yutani, S., Shichijo, S., Inoue, Y., Kawagoe, N., Okuda, K., Kurohiji, T. ... Itoh, K. (2001). Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas. Oncology Reports, 8, 369-372. https://doi.org/10.3892/or.8.2.369
MLA
Yutani, S., Shichijo, S., Inoue, Y., Kawagoe, N., Okuda, K., Kurohiji, T., Tanaka, M., Sata, M., Itoh, K."Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas". Oncology Reports 8.2 (2001): 369-372.
Chicago
Yutani, S., Shichijo, S., Inoue, Y., Kawagoe, N., Okuda, K., Kurohiji, T., Tanaka, M., Sata, M., Itoh, K."Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas". Oncology Reports 8, no. 2 (2001): 369-372. https://doi.org/10.3892/or.8.2.369